Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

INSM – Insmed Incorporated

Insmed Incorporated
INSM
$108.69
Name : Insmed Incorporated
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $20,645,775,360.00
EPSttm : -5.93
finviz dynamic chart for INSM
Insmed Incorporated
$108.69
1.31%
$1.41

Float Short %

5.22

Margin Of Safety %

Put/Call OI Ratio

1.03

EPS Next Q Diff

0.05

EPS Last/This Y

0.38

EPS This/Next Y

1.59

Price

108.69

Target Price

115.06

Analyst Recom

1.05

Performance Q

49.63

Relative Volume

0.63

Beta

0.95

Ticker: INSM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04INSM97.81.140.9976338
2025-07-07INSM96.921.121.7882347
2025-07-08INSM96.141.131.5982845
2025-07-09INSM96.441.110.3782790
2025-07-10INSM96.631.061.2686270
2025-07-11INSM98.221.070.3486400
2025-07-14INSM101.891.070.4086756
2025-07-15INSM102.861.060.6987757
2025-07-16INSM104.581.050.5993015
2025-07-17INSM104.181.080.6991579
2025-07-18INSM102.551.080.8692078
2025-07-21INSM102.760.932.0776117
2025-07-22INSM102.920.932.1376842
2025-07-23INSM103.450.940.7778450
2025-07-24INSM103.530.940.2279271
2025-07-25INSM103.950.940.5980239
2025-07-28INSM101.880.943.9580861
2025-07-29INSM104.851.081.0187316
2025-07-30INSM105.071.070.1488279
2025-07-31INSM107.321.070.0488889
2025-08-01INSM108.71.030.4590743
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04INSM97.8032.216.9-5.19
2025-07-07INSM96.9532.220.8-5.19
2025-07-08INSM96.1432.220.5-5.19
2025-07-09INSM96.4732.29.7-5.19
2025-07-10INSM96.6632.211.0-5.19
2025-07-11INSM98.1832.2-3.4-5.19
2025-07-14INSM101.8932.2-21.9-5.19
2025-07-15INSM102.8732.24.0-5.19
2025-07-16INSM104.5732.2-2.4-5.19
2025-07-17INSM104.1732.216.5-5.19
2025-07-18INSM102.5532.227.1-5.19
2025-07-21INSM102.7932.210.7-5.19
2025-07-22INSM102.9332.211.5-5.19
2025-07-23INSM103.4432.28.2-5.19
2025-07-24INSM103.5232.312.1-5.19
2025-07-25INSM103.9532.39.0-5.19
2025-07-28INSM101.8632.331.3-5.19
2025-07-29INSM105.0032.3-16.5-5.19
2025-07-30INSM105.1832.311.4-5.19
2025-07-31INSM107.2832.3-5.5-5.19
2025-08-01INSM108.6932.31.2-5.19
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04INSM-23.264.216.27
2025-07-07INSM-23.264.216.27
2025-07-08INSM-23.264.216.27
2025-07-09INSM-24.054.216.27
2025-07-10INSM-24.054.216.27
2025-07-11INSM-23.134.215.27
2025-07-14INSM-23.134.405.27
2025-07-15INSM-23.334.405.27
2025-07-16INSM-23.334.405.27
2025-07-17INSM-22.744.405.27
2025-07-18INSM-22.744.405.27
2025-07-21INSM-22.744.995.27
2025-07-22INSM-22.744.995.27
2025-07-23INSM-23.554.995.27
2025-07-24INSM-23.554.995.27
2025-07-25INSM-23.554.995.22
2025-07-28INSM-23.550.905.22
2025-07-29INSM-23.550.905.22
2025-07-30INSM-23.550.905.22
2025-07-31INSM-23.550.905.22
2025-08-01INSM-22.270.905.22
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.42

Avg. EPS Est. Current Quarter

-1.31

Avg. EPS Est. Next Quarter

-1.37

Insider Transactions

-22.27

Institutional Transactions

0.9

Beta

0.95

Average Sales Estimate Current Quarter

103

Average Sales Estimate Next Quarter

113

Fair Value

Quality Score

29

Growth Score

51

Sentiment Score

91

Actual DrawDown %

Max Drawdown 5-Year %

-63.3

Target Price

115.06

P/E

Forward P/E

PEG

P/S

54.18

P/B

199.38

P/Free Cash Flow

EPS

-5.95

Average EPS Est. Cur. Y​

-5.19

EPS Next Y. (Est.)

-3.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-265.93

Relative Volume

0.63

Return on Equity vs Sector %

-1045.6

Return on Equity vs Industry %

-1026.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

1.2
Insmed Incorporated
Sector: Healthcare
Industry: Biotechnology
Employees: 1271
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
stock quote shares INSM – Insmed Incorporated Stock Price stock today
news today INSM – Insmed Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch INSM – Insmed Incorporated yahoo finance google finance
stock history INSM – Insmed Incorporated invest stock market
stock prices INSM premarket after hours
ticker INSM fair value insiders trading